Somewhat Favorable News Coverage Somewhat Unlikely to Impact Baxter International (NYSE:BAX) Stock Price

News articles about Baxter International (NYSE:BAX) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Baxter International earned a news impact score of 0.16 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 46.2796945451641 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news stories that may have effected Accern’s rankings:

Baxter International (NYSE:BAX) traded down $0.67 during trading hours on Tuesday, hitting $67.67. 4,225,500 shares of the stock traded hands, compared to its average volume of 3,227,280. Baxter International has a one year low of $45.47 and a one year high of $69.65. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.22 and a current ratio of 2.80. The company has a market cap of $36,920.00, a P/E ratio of 36.58, a price-to-earnings-growth ratio of 2.05 and a beta of 0.69.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.05. Baxter International had a net margin of 9.88% and a return on equity of 15.00%. The firm had revenue of $2.71 billion for the quarter, compared to analyst estimates of $2.66 billion. During the same period in the previous year, the business earned $0.56 earnings per share. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. research analysts forecast that Baxter International will post 2.43 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 1st were paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date was Thursday, November 30th. Baxter International’s dividend payout ratio (DPR) is 34.59%.

BAX has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $72.00 price target on the stock in a research report on Tuesday, October 24th. Royal Bank of Canada restated a “hold” rating and issued a $66.00 price target on shares of Baxter International in a research report on Wednesday, November 22nd. Bank of America restated a “hold” rating on shares of Baxter International in a research report on Wednesday, November 22nd. Morgan Stanley raised their price objective on shares of Baxter International from $59.00 to $62.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 26th. Finally, Cowen reaffirmed a “neutral” rating on shares of Baxter International in a research note on Friday, October 13th. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $68.64.

In other news, Director Third Point Llc sold 5,000,000 shares of the stock in a transaction on Monday, November 6th. The shares were sold at an average price of $64.23, for a total transaction of $321,150,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Jeanne K. Mason sold 33,350 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $65.25, for a total transaction of $2,176,087.50. Following the transaction, the senior vice president now owns 124,609 shares of the company’s stock, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. Insiders sold 5,061,991 shares of company stock valued at $325,245,035 in the last ninety days. Insiders own 0.05% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Baxter International (NYSE:BAX) Stock Price” was originally published by BBNS and is the sole property of of BBNS. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://baseballnewssource.com/markets/baxter-international-bax-earns-coverage-optimism-score-of-0-16/1821305.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Insider Buying and Selling by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.